Mottet NBellmunt JBriers E. EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer. Presented at the 2018 EAU Annual Congress; Copenhagen Denmark; March 16–20 2018. Available at: https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf. Accessed January 1 2019.
Mohler JLLee RJAntonarakis ES. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3.2018. To view the most recent version of these guidelines visit NCCN.org. Accessed July 12 2018.
Lu-Yao GLAlbertsen PCMoore DF. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173–181.
Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006;97:243–247.
Stephenson AJKattan MWEastham JA. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–4305.
Cooperberg MRGrossfeld GDLubeck DP. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981–989.
Akaza HHomma YUsami M. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006;98:573–579.
Ueno SNamiki MFukagai T. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006;13:1494–1500.
Cooperberg MRHinotsu SNamiki M. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int 2016;117:102–109.
Akaza H. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010;85:110–120.
Akaza HUmbas RCheng JCH. NCCN Clinical Practice Guidelines in Oncology-Asia Consensus Statement: Prostate Cancer. Version 2.2013. To view the most recent version of these guidelines visit NCCN.org. Accessed July 12 2018.
Ozono SHinotsu SNamiki M. NCCN Asian consensus statement - can Asian patients with cancer accept treatment modalities from NCCN guidelines [in Japanese]? Gan To Kagaku Ryoho 2014;41:683–686.
Potosky ALHaque RCassidy-Bushrow AE. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol 2014;32:1324–1330.
Kuo YFMontie JEShahinian VB. Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer. Med Care 2012;50:374–380.
Holmberg LBill-Axelson ASteineck G. Results from the Scandinavian Prostate Cancer Group Trial number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting. J Natl Cancer Inst Monogr 2012;2012:230–233.
- Search Google Scholar
- Export Citation
)| false . , Holmberg L , Bill-Axelson A , Steineck G Results from the Scandinavian Prostate Cancer Group Trial number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting. 2012; 2012: 230– 233. 23271778 10.1093/jncimonographs/lgs025
Gandaglia GSun MTrinh QD. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. BJU Int 2014;114:E62–E69.
Bill-Axelson AHolmberg LGarmo H. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Shahinian VBKuo YFFreeman JL. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006;98:839–845.
Kuykendal ARHendrix LHSalloum RG. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol 2013;24:1338–1343.
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46–61.
Schymura MJKahn ARGerman RR. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 2010;10:152.
Matsumoto KHagiwara MTanaka N. Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population. Med Oncol 2014;31:979.
- Search Google Scholar
- Export Citation
)| false . , Matsumoto K , Hagiwara M , Tanaka N Survival following primary androgen deprivation therapy for localized intermediate- or high-risk prostate cancer: comparison with the life expectancy of the age-matched normal population. 2014; 31: 979. 10.1007/s12032-014-0979-3 24781338
Kitagawa YUeno SKonaka H. Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. Curr Cancer Drug Targets 2015;15:314–326.